secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2023-07-11T23:59:59+00:00
Accession:  0001798749-23-000048
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aerovate appoints former Acceleron CEO Habib Dable to Board of Directors
------------------------------------------------------------------------

- Habib Dable appointed to Board effective July 10, 2023 as Class II director through 2026.
- Dable was President/CEO of Acceleron, which sold to Merck in 2021 for >$11B.
- He brings nearly 30 years of biopharma experience, including roles at Bayer and RA Capital.
- Dable will serve on the Compensation Committee alongside Iwicki and Katabi.
- Company continues advancing AV-101, inhaled imatinib, for pulmonary arterial hypertension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000179874923000048/0001798749-23-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000179874923000048/tmb-20230710x8k.htm
  HTML page:      https://secwatch.observer/filing/0001798749-23-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer